Literature DB >> 10220835

Pulmonary hypertension in systemic lupus erythematosus.

J Y Shen1, S L Chen, Y X Wu, R Q Tao, Y Y Gu, C D Bao, Q Wang.   

Abstract

A prospective echocardiographic and clinical study was performed on 84 Chinese patients with systemic lupus erythematosus (SLE) and 99 controls to investigate the prevalence and the mechanism of pulmonary hypertension (PH) in SLE. Comparison between Doppler estimation and catheterization measurement was made in 12 cases to validate the predictive method. Compared to normal subjects, lupus patients had significantly increased systolic pulmonary artery pressure (SPAP) (29.59 +/- 12.52 vs 19.64 +/- 5.82, P < 0.001), mean pulmonary artery pressure (MPAP) (15.11 +/- 7.36 vs 10.21 +/- 4.72, P < 0.001) and total pulmonary resistance (TPR) (315.85 +/- 190.65 vs 220.37 +/- 55.92, P < 0.001). Nine of the 84 patients presented PH, defined as SPAP < 30 mmHg and MPAP > 20 mmHg. Pulmonary hypertensive patients had higher serum endothelin (ET) than non-pulmonary hypertensive patients, were more commonly in active stages, and presented Raynaud's phenomenon and rheumatoid factors. ET level was correlated with echocardiographic pulmonary pressure. Pulmonary hypertension commonly occurs in Chinese patients with SLE (11%), and it correlates with the lupus activity and the elevation of serum endothelin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220835     DOI: 10.1007/s002960050074

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  17 in total

1.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

2.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

3.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.

Authors:  Jahidur Rashid; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-11       Impact factor: 5.464

5.  Accuracy of noninvasively determined pulmonary artery systolic pressure.

Authors:  Jeffrey M Testani; Martin G St John Sutton; Susan E Wiegers; Amit V Khera; Richard P Shannon; James N Kirkpatrick
Journal:  Am J Cardiol       Date:  2010-03-05       Impact factor: 2.778

Review 6.  Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.

Authors:  Anupama Shahane
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

7.  Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation.

Authors:  Undurti N Das
Journal:  J Inflamm Res       Date:  2010-12-02

Review 8.  Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction.

Authors:  Atiya Dhala
Journal:  Clin Dev Immunol       Date:  2012-03-22

Review 9.  Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population.

Authors:  Y K Xia; S H Tu; Y H Hu; Y Wang; Z Chen; H T Day; K Ross
Journal:  Rheumatol Int       Date:  2012-09-16       Impact factor: 2.631

10.  Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.

Authors:  C P Denton; J E Pope; H-H Peter; A Gabrielli; A Boonstra; F H J van den Hoogen; G Riemekasten; S De Vita; A Morganti; M Dölberg; O Berkani; L Guillevin
Journal:  Ann Rheum Dis       Date:  2007-11-30       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.